Migraine drug that treats headache also eases symptoms like dizziness

A groundbreaking discovery has been made in the field of migraine treatment, with the identification of a drug called ubrogepant that not only alleviates migraine headaches but also targets the non-headache symptoms that precede a migraine attack. This development marks a significant advancement in migraine therapy, as previous treatments have primarily focused on managing the headache itself, neglecting the early warning signs that can severely impact an individual’s daily functioning.

Prior to the onset of a migraine headache, many individuals experience a prodrome phase characterized by warning symptoms like sensitivity to light or sound, dizziness, and neck stiffness. These prodromal symptoms can be disruptive and debilitating on their own, underscoring the need for effective interventions targeting these early manifestations of migraine.

Researchers, led by Peter Goadsby at King’s College London, conducted a study involving 438 participants with a history of migraines to investigate the efficacy of ubrogepant in addressing both the headache and non-pain symptoms associated with migraines. The participants were instructed to take either a 100-milligram dose of ubrogepant or a placebo at the onset of prodromal symptoms, and then switch to the alternative treatment during the next episode of early symptoms.

The results of the study revealed that individuals who took ubrogepant reported improvements in concentration within an hour, decreased sensitivity to light after 2 hours, and reduced fatigue and neck pain after 3 hours, compared to when they took the placebo. Additionally, dizziness and sensitivity to sound were also alleviated with the administration of ubrogepant.

Goadsby emphasized the significance of these findings, stating that ubrogepant not only targets the pain associated with migraines but also mitigates the non-pain symptoms, offering relief before the onset of the headache phase. The study did not specifically address the drug’s impact on aura, another early symptom characterized by sensory disturbances affecting vision.

Parisa Gazerani, a researcher at Oslo Metropolitan University, highlighted the clinical relevance of intervening early in the migraine cascade to address functionally disabling prodromal symptoms. While further research is needed to validate the broad applicability of ubrogepant, the potential of migraine treatments to alleviate early symptoms holds promise for enhancing the quality of life for individuals living with migraines.

Rob Music, who heads The Migraine Trust in the UK, lauded the research for its potential to reduce the impact of migraines on individuals, noting the importance of continued investigation in this area to support the millions affected by this condition.